Mineralys Therapeutics Inc. (MLYS) Live Share Price, Invest From India

Mineralys Therapeutics Inc. Stock Performance

as on June 27, 2026 at 2:15 pm IST

Day's Low
Day's High
$25.44
Day's Price Range
$26.77
$26.68
4.65%
Downside
0.34%
Upside
52 Week's Low
52 Week's High
$12.59
52-Week Price Range
$47.65
$26.68
52.81%
Downside
78.60%
Upside

Mineralys Therapeutics Inc. share price movements today

Previous Close: $26.34
Open: $26.10
Volume: 1.4M
Day's Low - High: $25.44 - $26.77
52 Week Low - High: $12.59 - $47.65

Mineralys Therapeutics Inc. Historical Returns

1 Month Return: -12.17 %
3 Month Return: + 11.56 %
1 Year Return: + 88.14 %
3 Year Return: + 72.16 %
5 Year Return: 0 %

Mineralys Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Mineralys Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.3B

EPS (TTM)

-2.2388

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-171.4M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-30.99%

Mineralys Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mineralys Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Mineralys Therapeutics Inc.	BUY	$2.3B	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.3B	67.15%	74.07	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$120.6B	147.08%	28.17	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$65.4B	12.64%	15.22	29.65%	0.58%

Stock Returns calculator for Mineralys Therapeutics Inc. Stock including INR - Dollar returns

The Mineralys Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Mineralys Therapeutics Inc. investment value today

Current value as on today

₹2,10,296

Returns

₹1,10,296

(+110.3%)

Returns from Mineralys Therapeutics Inc. Stock

₹90,571 (+90.57%)

Dollar Impact

₹19,725 (+19.73%)

Analyst Recommendation on Mineralys Therapeutics Inc. Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.31% of analysts recommend a 'BUY' rating for Mineralys Therapeutics Inc.. Average target price of $49

Mineralys Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Mineralys Therapeutics Inc..

What analysts predicted

45.55%UPSIDE

Target Price

$49

Current Price

$26.68

Analyzed by

13 Analysts

Target

$49.00

Mineralys Therapeutics Inc. target price $49, a slight upside of 45.55% compared to current price of $26.68. According to 13 analysts rating.

Indian Investors' Interest in Mineralys Therapeutics Inc. Stock

Search interest for Mineralys Therapeutics Inc. Stock has increased by 158% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 29, 2026 to June 28, 2026

Change:158% versus previous 30 day period

Mineralys Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	0	-	-	-	-	-
Gross Profit	-	0	0	0	0	0	0	0	0	0
Operating Income	-27	-35	-45	-60	-51	-44	-46	-41	-38	-45
EBITDA	-24	-31	-41	-56	-48	-42	-43	-36	-32	-39
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-24	-31	-41	-56	-48	-42	-43	-36	-32	-39
Income Tax Expense	0	0	-	-	-	-	-	-	-	-
Net Income	-24	-31	-41	-56	-48	-42	-43	-36	-32	-39
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-143958.82%	0.00%	0.00%	0.00%	0.00%	0.00%

Mineralys Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	0	0
Operating Income	-2	-18	-31	-84	-192	-170
EBITDA	-3	-19	-31	-71	-177	-154
Interest Expense	0	0	1	-	-	-
Depreciation	-	-	-	-	0	0
Income Before Tax	-3	-19	-29	-71	-177	-154
Income Tax Expense	0	0	-1	0	-177	-
Net Income	-3	-19	-29	-71	-177	-154
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Mineralys Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-31	-41	-56	-48	-42	-43	-36	-32	-39
Operating Cash Flow	-19	-30	-50	-66	-45	-30	-28	-37	-39
Investing Cash Flow	-55	7	79	83	-92	-42	-150	-103	-44
Financing Cash Flow	116	0	0	0	189	9	295	96	24
Change in Cash	41	-22	29	16	50	-63	115	-44	-60

Mineralys Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-19	-29	-71	-177	-154
Operating Cash Flow	-14	-29	-81	-166	-142
Investing Cash Flow	-21	-21	-160	114	-389
Financing Cash Flow	23	128	203	116	590
Change in Cash	9	77	-38	64	58

Global Institutional Holdings in Mineralys Therapeutics Inc.

Funds	Holdings
Catalys Pacific LLC	9.69%
Polar Capital Holdings PLC	1.84%
Geode Capital Management, LLC	1.58%
Wellington Management Company LLP	4.12%
Jennison Associates LLC	1.53%

See all

Insights on Mineralys Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, MLYS has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 7 days, MLYS stock has moved up by 8.3%
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, MLYS has outperformed top 5 stocks with highest market-cap in its industry

About Mineralys Therapeutics Inc.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Organisation	Mineralys Therapeutics Inc.
Headquarters	150 N. Radnor Chester Road, Radnor, PA, United States, 19087
Industry	Biotechnology
CEO	Dr. Jon Congleton
E-voting on shares	Click here to vote

Key Management of Mineralys Therapeutics Inc.

Name	Title
Ms. Danielle Mahoney	Senior Vice President of Quality Assurance
Ms. Jessica Ibbitson	Executive Vice President of Operations
Ms. Tiffany Ellen Burt	Senior Vice President of Medical Affairs
Dr. Jon Congleton	President, CEO & Director
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.	Founder & Executive Director
Mr. Adam Scott Levy	CFO & Secretary
Dr. David M. Rodman M.D.	Chief Medical Officer
Mr. Jeffrey A. Munsie J.D.	Chief Legal Officer
Dr. Robert McKean Ph.D.	Senior Vice President of CMC
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer

FAQs

What is Mineralys Therapeutics Inc. share price today?

Mineralys Therapeutics Inc. share price today is $26.68 as on June 27, 2026 at 8:45 am IST at the close of the market. Mineralys Therapeutics Inc. share today touched a day high of $26.77 and a low of $25.44.

What is the 52 week high and 52 week low for Mineralys Therapeutics Inc. share?

Mineralys Therapeutics Inc. share touched a 52 week high of $47.65 on November 12, 2025 and a 52 week low of $12.59 on August 13, 2025. Mineralys Therapeutics Inc. stock price today i.e. June 27, 2026 at 8:45 am IST is closed at $26.68,which is 44.01% down from its 52 week high and 111.91% up from its 52 week low.

What is Mineralys Therapeutics Inc.'s market capitalisation today?

Mineralys Therapeutics Inc. market capitalisation is $0.00T as on June 27, 2026 at 8:45 am IST.

How to invest in Mineralys Therapeutics Inc. Stock (MLYS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mineralys Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mineralys Therapeutics Inc. Shares that will get you 0.0562 shares as per Mineralys Therapeutics Inc. share price of $26.68 per share as on June 27, 2026 at 8:45 am IST.

What is the minimum amount required to buy Mineralys Therapeutics Inc. Stock (MLYS) from India?

Indian investors can start investing in Mineralys Therapeutics Inc. (MLYS) shares with as little as ₹94.3 or $1 (as of June 28, 2026 at 9:43 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.00 in Mineralys Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 28, 2026 at 9:43 am IST). Based on Mineralys Therapeutics Inc. share’s latest price of $26.68 as on June 27, 2026 at 8:45 am IST, you will get 0.3748 shares of Mineralys Therapeutics Inc.. Learn more about fractional shares .